Index
Module 10 • Neurology
Neurocritical Care
72%
Data Tables
Neurocritical Care
Keaton S. Smetana ~3 min read Module 10 of 20
38
/ 53

Neurocritical Care

B.Diagnosis/Pathogenesis – Diagnostic tests
1

Contrast-enhanced MRI is the most common test.

2Biopsy is often necessary to reveal the specific histology.
C.Clinical Impact – Mortality is often high, depending on the type and grade of the tumor.
D.Treatment Considerations
1

Corticosteroids for brain edema

Dexamethasone commonly used for vasogenic edema associated with tumors

Reduces peritumoral edema and symptoms associated with increased ICP. Temporarily

reduces symptoms (neurologic dysfunction, seizures, headache)

ii.

Dose is commonly 4 mg intravenously every 6 hours.

iii.

May use other corticosteroids at comparable doses

Use of acid-suppressive agents (famotidine) may help with concomitant steroid use to reduce the risk

of GI complications (Wien Med Wochenschr 1988;138:97-101).

Consideration for glycemic control

d.Induction of phenytoin metabolism (because of increased metabolic rate)

Metabolism induced by phenytoin (because of increased cytochrome P450 [CYP] activity)

2VTE prophylaxis and treatment

High risk of VTE

Consider using combination pharmacologic/mechanical prophylaxis.

Enoxaparin is superior to warfarin for the treatment of VTE in oncology patients.

3

Seizure prophylaxis

Not typically indicated

Around 50% of patients with primary brain tumor present with seizure, which must be treated with

anticonvulsant medications.

Phenytoin, carbamazepine, and levetiracetam are often recommended; however, caution should

be used with agents that have been associated with Stevens-Johnson syndrome/toxic epidermal

necrolysis (e.g., phenytoin, carbamazepine) in patients who also require radiation therapy.

d.Hepatic CYP enzyme-inducing agents, including phenytoin, should be used with caution because

of possible drug interactions with chemotherapy.

XIII.CRITICAL ILLNESS POLYNEUROPATHY
A.Epidemiology
1

Exact incidence is unknown because of inconsistent monitoring and diagnosis.

2May be as high as 60% in patients with acute respiratory distress syndrome, 77% in long ICU stay

(greater than 7 days), 80% in patients with multiorgan failure

B.Diagnosis/Pathogenesis – Diagnostic tests
1

Typically suspected when patients do not wean well from the ventilator or if their limbs are weak/flaccid

2Electrophysiologic studies or muscle biopsy may provide a more precise diagnosis. Differential diagnosis

includes evaluation for critical illness myopathy, Guillain-BarrΓ© syndrome, electrolyte abnormalities

C.Causes
1

The cause of critical illness polyneuropathy is unknown, but several hypotheses exist.

Mitochondrial dysfunction in critical illness may cause energy stress in vulnerable neurons.

Ψ΄Ψ±Ψ­ Ψ§Ω„ΩΩŠΨ―ΩŠΩˆ Ψ§Ω„ΨͺΨΉΩ„ΩŠΩ…ΩŠ β€” Ω…Ψ²Ψ§Ω…Ω†Ψ© Ω…ΨΉ Ψ§Ω„Ω€ PDF
Ψ¨Ψ―Ψ‘ Ψ§Ω„ΨͺΨ΄ΨΊΩŠΩ„ Ω…Ω†: Ψ§Ω„Ψ―Ω‚ΩŠΩ‚Ψ© 37 فΨͺΨ­ ΨΉΩ„Ω‰ YouTube